10月6日周一盘前，生物制药巨头吉利德科学（GILD）股价大涨5.10%，引发市场广泛关注。
根据公司向美国证券交易委员会（SEC）提交的文件显示，吉利德科学已与印度制药公司Lupin、Cipla和Laurus Labs达成和解协议，以解决有关其重要药物Biktarvy的专利诉讼。Biktarvy是吉利德科学用于治疗HIV感染的重要产品之一，此次和解协议的达成无疑消除了市场对该产品未来销售的不确定性。
分析人士认为，这一和解协议对吉利德科学具有积极影响。首先，它有助于保护Biktarvy的市场地位，维护公司在HIV治疗领域的领先地位。其次，避免了长期法律纠纷可能带来的高额成本和负面影响。最后，这一决定也显示了公司在知识产权管理方面的策略性和灵活性，有利于公司长期发展。投资者对这一消息反应积极，推动了股价的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.